REVIEW article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1556377
This article is part of the Research TopicImmunological Aspects and Immunotherapy in Gynecologic CancersView all 10 articles
Unveiling Drug Resistance Pathways in High-Grade Serous Ovarian Cancer(HGSOC): Recent Advances and Future Perspectives
Provisionally accepted
- 1Gynaecology department of The First Affiliated Hospital, Shihezi University, Shihezi, Xinjiang Uyghur Region, China
- 2Peripheral vascular disease department of The First Affiliated Hospital, Heilongjiang University of Traditional Chinese Medicine, Harbin, Jilin Province, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
High-Grade Serous Ovarian Carcinoma (HGSOC) represents the most prevalent and lethal subtype of ovarian cancer, with approximately 225,000 new cases reported globally each year and a five-year survival rate of merely 49.1%. The clinical management of HGSOC encounters substantial challenges, primarily attributable to its intricate drug resistance mechanisms, which involve multiple biological processes, including tumor cell heterogeneity, microenvironment remodeling, gene mutations, and drug efflux. This study systematically reviews the most recent advancements in HGSOC drug resistance research, concentrating on the molecular biological foundations of resistance mechanisms, innovative detection strategies, and potential therapeutic approaches. The research indicates that HGSOC drug resistance constitutes a complex process characterized by multifactorial interactions, involving aberrant cell signaling pathways, dynamic alterations in the tumor microenvironment, and specific expressions of molecular markers. In this review, we systematically analyzed and investigated the intricate biological behaviors associated with HGSOC drug resistance, which not only enhances the understanding of disease progression but also provides essential theoretical foundations for the development of more precise and effective targeted therapies. This review firstly illustrated the detailed drug resistance cellular and molecular mechanisms underlying HGSOC chemotherapy, which can pave the way for future studies in HGSOC drug resistance practices.
Keywords: High-grade serous ovarian carcinoma (HGSOC), Drug resistance mechanisms, Molecular markers, personalized treatment, Tumor Microenvironment
Received: 06 Jan 2025; Accepted: 14 Apr 2025.
Copyright: © 2025 Fu, Hu, Li, Lv, Zhao and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Ruiting Fu, Gynaecology department of The First Affiliated Hospital, Shihezi University, Shihezi, Xinjiang Uyghur Region, China
Hanwei Zhao, Peripheral vascular disease department of The First Affiliated Hospital, Heilongjiang University of Traditional Chinese Medicine, Harbin, Jilin Province, China
Fuxia Li, Gynaecology department of The First Affiliated Hospital, Shihezi University, Shihezi, Xinjiang Uyghur Region, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.